COVID-19-induced latent relapsing hypercoagulable state in the absence of persistent viral infection

Adrija Hajra; Juan Torrado; Carlos L Alviar; Sripal Bangalore; Norma Keller; Robert Faillace; Seth Sokol

doi:10.1177/2050313X221113934

COVID-19-induced latent relapsing hypercoagulable state in the absence of persistent viral infection

SAGE Open Med Case Rep. 2022 Jul 22:10:2050313X221113934. doi: 10.1177/2050313X221113934. eCollection 2022.

Authors

Adrija Hajra¹, Juan Torrado¹, Carlos L Alviar², Sripal Bangalore², Norma Keller², Robert Faillace¹, Seth Sokol³

Affiliations

¹ Department of Internal Medicine, New York City Health and Hospitals-Jacobi Medical Center, New York, NY, USA.
² Department of Cardiology, New York City Health and Hospitals-Bellevue, New York, NY, USA.
³ Division of Cardiology, Department of Medicine, New York City Health and Hospitals-Jacobi Medical Center, New York, NY, USA.

Abstract

Hypercoagulability in coronavirus disease 2019 infection is already a known fact. But in this article, we have discussed a unique case where the patient had suffered from relapsing thrombus formation. This report describes the case of a patient who presented with chronic coronavirus disease 2019-induced recurrent thrombi refractory to multiple antithrombotic regimens because of multiple recurrent inflammatory flares without any evidence of chronic persistent viral infection. The patient was treated with anticoagulation and anti-inflammatory medications. Still, he had repeated episodes of right ventricular thrombus. Coronavirus disease 2019 can provoke a severe relapsing hypercoagulable state without evidence of persisting viral infection. Rebound inflammatory flares rather than viral recurrence may play a trigger.

Keywords: COVID-19; anticoagulation; pulmonary embolism; right ventricular thrombus; thrombosis.

Publication types

Case Reports